PARIS
Cerba HealthCare is pursuing court-supervised restructuring of approximately €5 billion ($5.8 billion) in debt, marking an inflection point for how European private equity portfolio companies manage leverage in a higher rate environment.
The French medical diagnostics provider, backed by EQT AB, has built an extensive network of laboratories across multiple European markets. However, its debt burden has become difficult to service as refinancing costs have climbed. The formal restructuring process gives the company a structured framework to renegotiate with lenders and shareholders while operating under court protection.
The timing reflects a structural shift in European credit markets. Companies that accumulated substantial debt during the 2010-2021 period of historically cheap financing are now facing a materially different debt-servicing equation. When rates were near zero, a €5 billion debt load on stable, essential-services cash flows was manageable. At current rates, the same obligation has become unsustainable for weaker credit profiles.
For Cerba's lenders, the restructuring could involve modified repayment schedules, reduced interest rates, extended maturities, or outright haircuts. The outcome will depend on negotiations between creditors and the company's equity sponsor, EQT.
A portion of Cerba's revolving credit facility is reportedly available for sale as the company advances through proceedings. This signals active asset-level engagement by stakeholders seeking to improve the capital structure.
The case carries relevance for European credit investors monitoring large leveraged financings. It demonstrates how even businesses in structurally resilient sectors—medical diagnostics remains essential infrastructure—can face balance sheet stress if leverage is mismatched to cost-of-capital assumptions.
